A longitudinal study on the relationship between duration of untreated psychosis and executive function in early-onset first-episode psychosis

Schizophrenia Research

Volumn 158, Issue 1-3, 2014, Pages 126-133

  Fraguas, David ^a   Merchán Naranjo, Jessica ^a   del Rey Mejías, Ángel ^a   Castro Fornieles, Josefina ^b   González Pinto, Ana ^c   Rapado Castro, Marta ^a,d,e   Pina Camacho, Laura ^a,f   Díaz Caneja, Covadonga M ^a   Graell, Montserrat ^g   Otero, Soraya ^h   Baeza, Inmaculada ^b   Moreno, Carmen ^a   Martínez Cengotitabengoa, Mónica ^c,i   Rodríguez Toscano, Elisa ^a   Arango, Celso ^a   Parellada, Mara ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^h HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

ⁱ UNIVERSIDAD NACIONAL DE EDUCACIÓN A DISTANCIA   (Spain)

Author keywords

Adolescents; Attention; Children; Cognition; Cognitive flexibility; Executive function; Problem solving; Response inhibition; Schizophrenia; Working memory

Indexed keywords

CHLORPROMAZINE;

ADOLESCENT; ARTICLE; ATTENTION; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DURATION OF UNTREATED PSYCHOSIS; EARLY INTERVENTION; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POSITIVE SYNDROME; PRIORITY JOURNAL; PROBLEM SOLVING; PSYCHOSIS; RESPONSE INHIBITION; WORKING MEMORY; CLINICAL TRIAL; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOTIC DISORDERS; STATISTICAL MODEL; TIME;

ADOLESCENT; EXECUTIVE FUNCTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; TIME FACTORS;

EID: 84906938368     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.06.038     Document Type: Article

References (91)

1. Addington J., Addington D. Symptom remission in first episode patients. Schizophr. Res. 2008, 106(2-3):281-285.
2. Amminger G.P., Henry L.P., Harrigan S.M., Harris M.G., Alvarez-Jimenez M., Herrman H., Jackson H.J., McGorry P.D. Outcome in early-onset schizophrenia revisited: findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study. Schizophr. Res. 2011, 131(1-3):112-119.
3. Andreasen N.C., Pressler M., Nopoulos P., Miller D., Ho B.C. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry 2010, 67(3):255-262.
4. Arango C., Fraguas D., Parellada M. Differential neurodevelopmental trajectories in patients with early-onset bipolar and schizophrenia disorders. Schizophr. Bull. 2014, 40(Suppl. 2):S138-S146.
5. Austin S.F., Mors O., Secher R.G., Hjorthoj C.R., Albert N., Bertelsen M., Jensen H., Jeppesen P., Petersen L., Randers L., Thorup A., Nordentoft M. Predictors of recovery in first episode psychosis: the OPUS cohort at 10year follow-up. Schizophr. Res. 2013, 150(1):163-168.
6. Barnes T.R., Leeson V.C., Mutsatsa S.H., Watt H.C., Hutton S.B., Joyce E.M. Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br. J. Psychiatry 2008, 193(3):203-209.
7. Barnett A.G., van der Pols J.C., Dobson A.J. Regression to the mean: what it is and how to deal with it. Int. J. Epidemiol. 2005, 34(1):215-220.
8. Bodnar M., Malla A., Joober R., Lepage M. Cognitive markers of short-term clinical outcome in first-episode psychosis. Br. J. Psychiatry 2008, 193(4):297-304.
9. Bombin I., Mayoral M., Castro-Fornieles J., Gonzalez-Pinto A., de la Serna E., Rapado-Castro M., Barbeito S., Parellada M., Baeza I., Graell M., Paya B., Arango C. Neuropsychological evidence for abnormal neurodevelopment associated with early-onset psychoses. Psychol. Med. 2013, 43(4):757-768.
10. Bora E., Murray R.M. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis?. Schizophr. Bull. 2014, 40(4):744-755.
11. Cannon-Spoor H.E., Potkin S.G., Wyatt R.J. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr. Bull. 1982, 8(3):470-484.
12. Carrion R.E., McLaughlin D., Goldberg T.E., Auther A.M., Olsen R.H., Olvet D.M., Correll C.U., Cornblatt B.A. Prediction of functional outcome in individuals at clinical high risk for psychosis. JAMA Psychiatry 2013, 70(11):1133-1142.
13. Castro-Fornieles J., Baeza I., de la Serna E., Gonzalez-Pinto A., Parellada M., Graell M., Moreno D., Otero S., Arango C. Two-year diagnostic stability in early-onset first-episode psychosis. J. Child Psychol. Psychiatry 2011, 52(10):1089-1098.
14. Castro-Fornieles J., Parellada M., Gonzalez-Pinto A., Moreno D., Graell M., Baeza I., Otero S., Soutullo C.A., Crespo-Facorro B., Ruiz-Sancho A., Desco M., Rojas-Corrales O., Patino A., Carrasco-Marin E., Arango C. The child and adolescent first-episode psychosis study (CAFEPS): design and baseline results. Schizophr. Res. 2007, 91(1-3):226-237.
15. Compton M.T., Carter T., Bergner E., Franz L., Stewart T., Trotman H., McGlashan T.H., McGorry P.D. Defining, operationalizing and measuring the duration of untreated psychosis: advances, limitations and future directions. Early Interv. Psychiatry 2007, 1:236-250.
16. Compton M.T., Gordon T.L., Weiss P.S., Walker E.F. The "doses" of initial, untreated hallucinations and delusions: a proof-of-concept study of enhanced predictors of first-episode symptomatology and functioning relative to duration of untreated psychosis. J. Clin. Psychiatry 2011, 72(11):1487-1493.
17. Conners K. Conners' Continuous Performance Test, CPT-II 2000, MHS.
18. Cuesta M.J., Garcia de Jalon E., Campos M.S., Ibanez B., Sanchez-Torres A.M., Peralta V. Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis. Schizophr. Res. 2012, 141(2-3):222-227.
19. Chan R.C., Shum D., Toulopoulou T., Chen E.Y. Assessment of executive functions: review of instruments and identification of critical issues. Arch. Clin. Neuropsychol. 2008, 23(2):201-216.
20. Diamond A. Executive functions. Annu. Rev. Psychol. 2013, 64:135-168.
21. Dominguez M.D., Fisher H.L., Major B., Chisholm B., Rahaman N., Joyce J., Woolley J., Lawrence J., Hinton M., Marlowe K., Aitchison K., Johnson S., Hodes M. Duration of untreated psychosis in adolescents: ethnic differences and clinical profiles. Schizophr. Res. 2013, 150(2-3):526-532.
22. Elliott R. Executive functions and their disorders. Br. Med. Bull. 2003, 65:49-59.
23. Emsley R., Rabinowitz J., Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr. Res. 2007, 89(1-3):129-139.
24. Erceg-Hurn D.M., Mirosevich V.M. Modern robust statistical methods: an easy way to maximize the accuracy and power of your research. Am. Psychol. 2008, 63(7):591-601.
25. Ezpeleta L., Granero R., de la Osa N. Evaluación del deterioro en niños y adolescentes a través de la Children's Global Assessment Scale (CGAS). Rev. Psiquiatr. Infanto-Juvenil 1999, 1:18-26.
26. Fraguas D., de Castro M.J., Medina O., Parellada M., Moreno D., Graell M., Merchan-Naranjo J., Arango C. Does diagnostic classification of early-onset psychosis change over follow-up?. Child Psychiatry Hum. Dev. 2008, 39(2):137-145.
27. Fraguas D., Del Rey-Mejias A., Moreno C., Castro-Fornieles J., Graell M., Otero S., Gonzalez-Pinto A., Moreno D., Baeza I., Martinez-Cengotitabengoa M., Arango C., Parellada M. Duration of untreated psychosis predicts functional and clinical outcome in children and adolescents with first-episode psychosis: a 2-year longitudinal study. Schizophr. Res. 2014, 152(1):130-138.
28. Goldberg T.E., Burdick K.E., McCormack J., Napolitano B., Patel R.C., Sevy S.M., Goldman R., Lencz T., Malhotra A.K., Kane J.M., Robinson D.G. Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia. Schizophr. Res. 2009, 107(2-3):262-266.
29. a ed.
30. Golden C.J. A group version of the Stroop Color and Word Test. J. Pers. Assess. 1975, 39(4):386-388.
31. Goldstein G., Watson J.R. Test-retest reliability of the Halstead-Reitan neuropsychological battery and the WAIS in the neuropsychiatric population. Clin. Neuropsychol. 1989, 3:265-273.
32. Gonzalez-Ortega I., de Los Mozos V., Echeburua E., Mezo M., Besga A., Ruiz de Azua S., Gonzalez-Pinto A., Gutierrez M., Zorrilla I. Working memory as a predictor of negative symptoms and functional outcome in first episode psychosis. Psychiatry Res. 2013, 206(1):8-16.
33. Heaton R., Chelune G., Talley J., HKay G., Curtiss G. WCST: test de clasificacion de tarjetas de Wisconsin 2001, TEA Ediciones, S.A., Madrid.
34. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12(3):426-445.
35. Huber G. The heterogeneous course of schizophrenia. Schizophr. Res. 1997, 28(2-3):177-185.
36. Jeppesen P., Petersen L., Thorup A., Abel M.B., Ohlenschlaeger J., Christensen T.O., Krarup G., Jorgensen P., Nordentoft M. The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. Psychol. Med. 2008, 38(8):1157-1166.
37. Juola P., Miettunen J., Veijola J., Isohanni M., Jaaskelainen E. Predictors of short- and long-term clinical outcome in schizophrenic psychosis - the Northern Finland 1966 Birth Cohort study. Eur. Psychiatry 2013, 28(5):263-268.
38. Jurado M.B., Rosselli M. The elusive nature of executive functions: a review of our current understanding. Neuropsychol. Rev. 2007, 17(3):213-233.
39. Kaufman J., Birmaher B., Brent D., Rao U., Flynn C., Moreci P., Williamson D., Ryan N. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J. Am. Acad. Child Adolesc. Psychiatry 1997, 36(7):980-988.
40. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
41. Koziol L.F., Lutz J.T. From movement to thought: the development of executive function. Appl. Neuropsychol. Child 2013, 2(2):104-115.
42. Kravariti E., Morgan K., Fearon P., Zanelli J.W., Lappin J.M., Dazzan P., Morgan C., Doody G.A., Harrison G., Jones P.B., Murray R.M., Reichenberg A. Neuropsychological functioning in first-episode schizophrenia. Br. J. Psychiatry 2009, 195(4):336-345.
43. Lappin J.M., Morgan K.D., Morgan C., Dazzan P., Reichenberg A., Zanelli J.W., Fearon P., Jones P.B., Lloyd T., Tarrant J., Farrant A., Leff J., Murray R.M. Duration of untreated psychosis and neuropsychological function in first episode psychosis. Schizophr. Res. 2007, 95(1-3):103-110.
44. Larsen T.K., Friis S., Haahr U., Johannessen J.O., Melle I., Opjordsmoen S., Rund B.R., Simonsen E., Vaglum P.V., McGlashan T.H. Premorbid adjustment in first-episode non-affective psychosis: distinct patterns of pre-onset course. Br. J. Psychiatry 2004, 185:108-115.
45. Larsen T.K., Melle I., Auestad B., Friis S., Haahr U., Johannessen J.O., Opjordsmoen S., Rund B.R., Simonsen E., Vaglum P., McGlashan T. Early detection of first-episode psychosis: the effect on 1-year outcome. Schizophr. Bull. 2006, 32(4):758-764.
46. Larsen T.K., Moe L.C., Vibe-Hansen L., Johannessen J.O. Premorbid functioning versus duration of untreated psychosis in 1year outcome in first-episode psychosis. Schizophr. Res. 2000, 45(1-2):1-9.
47. Leeson V.C., Barnes T.R., Hutton S.B., Ron M.A., Joyce E.M. IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis. Schizophr. Res. 2009, 107(1):55-60.
48. Lewandowski K.E., Cohen B.M., Ongur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol. Med. 2011, 41(2):225-241.
49. Lezak M. Neuropsychological Assessment 1995, Oxford University Press, New York, NY.
50. Lutgens D., Lepage M., Iyer S., Malla A. Predictors of cognition in first episode psychosis. Schizophr. Res. 2014, 152(1):164-169.
51. Malla A.K., Bodnar M., Joober R., Lepage M. Duration of untreated psychosis is associated with orbital-frontal grey matter volume reductions in first episode psychosis. Schizophr. Res. 2011, 125(1):13-20.
52. Marshall M., Lewis S., Lockwood A., Drake R., Jones P., Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch. Gen. Psychiatry 2005, 62(9):975-983.
53. Mayoral M., Zabala A., Robles O., Bombin I., Andres P., Parellada M., Moreno D., Graell M., Medina O., Arango C. Neuropsychological functioning in adolescents with first episode psychosis: a two-year follow-up study. Eur. Psychiatry 2008, 23(5):375-383.
54. McCrone P., Singh S.P., Knapp M., Smith J., Clark M., Shiers D., Tiffin P.A. The economic impact of early intervention in psychosis services for children and adolescents. Early Interv. Psychiatry 2013, 7(4):368-373.
55. Melle I., Larsen T.K., Haahr U., Friis S., Johannesen J.O., Opjordsmoen S., Rund B.R., Simonsen E., Vaglum P., McGlashan T. Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch. Gen. Psychiatry 2008, 65(6):634-640.
56. Mesholam-Gately R.I., Giuliano A.J., Goff K.P., Faraone S.V., Seidman L.J. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009, 23(3):315-336.
57. Morgan C., Abdul-Al R., Lappin J.M., Jones P., Fearon P., Leese M., Croudace T., Morgan K., Dazzan P., Craig T., Leff J., Murray R. Clinical and social determinants of duration of untreated psychosis in the AESOP first-episode psychosis study. Br. J. Psychiatry 2006, 189:446-452.
58. Nimon K.F. Statistical assumptions of substantive analyses across the general linear model: a mini-review. Front. Psychol. 2012, 3:322.
59. Norman R.M., Townsend L., Malla A.K. Duration of untreated psychosis and cognitive functioning in first-episode patients. Br. J. Psychiatry 2001, 179:340-345.
60. Nuechterlein K.H., Subotnik K.L., Green M.F., Ventura J., Asarnow R.F., Gitlin M.J., Yee C.M., Gretchen-Doorly D., Mintz J. Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophr. Bull. 2011, 37(Suppl. 2):S33-S40.
61. Paya B., Rodriguez-Sanchez J.M., Otero S., Munoz P., Castro-Fornieles J., Parellada M., Gonzalez-Pinto A., Soutullo C., Baeza I., Rapado-Castro M., Saenz-Herrero M., Moreno D., Arango C. Premorbid impairments in early-onset psychosis: differences between patients with schizophrenia and bipolar disorder. Schizophr. Res. 2013, 146(1-3):103-110.
62. Peralta Martín V., Cuesta Zorita M.J. Validation of positive and negative symptom scale (PANSS) in a sample of Spanish schizophrenic patients. Actas Luso Esp. Neurol. Psiquiatr. Cienc. Afines 1994, 22:171-177.
63. Perkins D.O., Gu H., Boteva K., Lieberman J.A. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am. J. Psychiatry 2005, 162(10):1785-1804.
64. Rapp C., Studerus E., Bugra H., Aston J., Tamagni C., Walter A., Pflueger M., Borgwardt S., Riecher-Rossler A. Duration of untreated psychosis and cognitive functioning. Schizophr. Res. 2013, 145(1-3):43-49.
65. Reichenberg A., Harvey P.D., Bowie C.R., Mojtabai R., Rabinowitz J., Heaton R.K., Bromet E. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr. Bull. 2009, 35(5):1022-1029.
66. Reltan R. Validity of the trail making test as an indication of organic brain damage. Percept. Mot. Skills 1959, 8:271-276.
67. Rijcken C.A., Monster T.B., Brouwers J.R., de Jong-van den Berg L.T. Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses?. J. Clin. Psychopharmacol. 2003, 23(6):657-659.
68. Rund B.R. Does active psychosis cause neurobiological pathology? A critical review of the neurotoxicity hypothesis. Psychol. Med. 2013, 1-14.
69. Rund B.R., Melle I., Friis S., Johannessen J.O., Larsen T.K., Midboe L.J., Opjordsmoen S., Simonsen E., Vaglum P., McGlashan T. The course of neurocognitive functioning in first-episode psychosis and its relation to premorbid adjustment, duration of untreated psychosis, and relapse. Schizophr. Res. 2007, 91(1-3):132-140.
70. Satler J. Assessment of Children Cognitive Applications 2001, San Diego State University Publisher Inc., San Diego, CA. 4th ed.
71. Schennach-Wolff R., Jager M., Mayr A., Meyer S., Kuhn K.U., Klingberg S., Heuser I., Klosterkotter J., Gastpar M., Schmitt A., Schlosser R., Schneider F., Gaebel W., Seemuller F., Moller H.J., Riedel M. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients-is it all about early response?. Eur. Neuropsychopharmacol. 2011, 21(5):370-378.
72. Schimmelmann B.G., Huber C.G., Lambert M., Cotton S., McGorry P.D., Conus P. Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J. Psychiatr. Res. 2008, 42(12):982-990.
73. Schottle D., Schimmelmann B.G., Conus P., Cotton S.M., Michel C., McGorry P.D., Karow A., Naber D., Lambert M. Differentiating schizoaffective and bipolar I disorder in first-episode psychotic mania. Schizophr. Res. 2012, 140(1-3):31-36.
74. Shaffer D., Gould M.S., Brasic J., Ambrosini P., Fisher P., Bird H., Aluwahlia S. A children's global assessment scale (CGAS). Arch. Gen. Psychiatry 1983, 40(11):1228-1231.
75. Shamsi S., Lau A., Lencz T., Burdick K.E., DeRosse P., Brenner R., Lindenmayer J.P., Malhotra A.K. Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr. Res. 2011, 126(1-3):257-264.
76. Soutullo C. Traducción al Español de la Entrevista Diagnóstica: Kiddie-Schedule for Affective Disorders & Schizophrenia, Present & Lifetime Version (K-SADS-PL, 1996) http://www.cun.es/la-clinica/departamentos-yservicios-medicos/psiquiatria-y-psicologia-medica/mas-sobreel-departamento/unidades/psiquiatria-infantil-y-adolescente.
77. Stafford M.R., Jackson H., Mayo-Wilson E., Morrison A.P., Kendall T. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 2013, 346:f185.
78. Strauss E., Sherman E., Spreen O. A Compendium of Neuropsychological Tests: Administration Norms and Commentary 2006, Oxford University Press, New York, NY. Third ed.
79. Tabares-Seisdedos R., Balanza-Martinez V., Sanchez-Moreno J., Martinez-Aran A., Salazar-Fraile J., Selva-Vera G., Rubio C., Mata I., Gomez-Beneyto M., Vieta E. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J. Affect. Disord. 2008, 109(3):286-299.
80. Townsend L.A., Norman R.M., Malla A.K., Rychlo A.D., Ahmed R.R. Changes in cognitive functioning following comprehensive treatment for first episode patients with schizophrenia spectrum disorders. Psychiatry Res. 2002, 113(1-2):69-81.
81. Twamley E.W., Burton C.Z., Vella L. Compensatory cognitive training for psychosis: who benefits? Who stays in treatment?. Schizophr. Bull. 2011, 37(Suppl. 2):S55-S62.
82. Ucok A., Direk N., Koyuncu A., Keskin-Ergen Y., Yuksel C., Guler J., Karadayi G., Akturan E., Devrim-Ucok M. Cognitive deficits in clinical and familial high risk groups for psychosis are common as in first episode schizophrenia. Schizophr. Res. 2013, 151(1-3):265-269.
83. van Os J., Murray R.M. Can we identify and treat "schizophrenia light" to prevent true psychotic illness?. BMJ 2013, 346:f304.
84. Verdoux H., Liraud F., Bergey C., Assens F., Abalan F., van Os J. Is the association between duration of untreated psychosis and outcome confounded? A two year follow-up study of first-admitted patients. Schizophr. Res. 2001, 49(3):231-241.
85. Vesterager L., Christensen T.O., Olsen B.B., Krarup G., Melau M., Forchhammer H.B., Nordentoft M. Cognitive and clinical predictors of functional capacity in patients with first episode schizophrenia. Schizophr. Res. 2012, 141(2-3):251-256.
86. Weschler D. WAIS-III, Wechsler adult intelligence scale third edition. Administration and Scoring Manual, San Antonio, TX 1997.
87. Wiersma D., Nienhuis F.J., Slooff C.J., Giel R. Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. Schizophr. Bull. 1998, 24(1):75-85.
88. Wunderink L., Sytema S., Nienhuis F.J., Wiersma D. Clinical recovery in first-episode psychosis. Schizophr. Bull. 2009, 35(2):362-369.
89. Yamazawa R., Nemoto T., Kobayashi H., Chino B., Kashima H., Mizuno M. Association between duration of untreated psychosis, premorbid functioning, and cognitive performance and the outcome of first-episode schizophrenia in Japanese patients: prospective study. Aust. N. Z. J. Psychiatry 2008, 42(2):159-165.
90. Zabala A., Rapado M., Arango C., Robles O., de la Serna E., Gonzalez C., Rodriguez-Sanchez J.M., Andres P., Mayoral M., Bombin I. Neuropsychological functioning in early-onset first-episode psychosis: comparison of diagnostic subgroups. Eur. Arch. Psychiatry Clin. Neurosci. 2010, 260(3):225-233.
91. Zipursky R.B., Reilly T.J., Murray R.M. The myth of schizophrenia as a progressive brain disease. Schizophr. Bull. 2013, 39(6):1363-1372.